Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- 21 The Global Market for Botulinum Toxin
- 22 Molecular Mechanisms of Botulinum Toxin
- 23 Indirect Central Nervous System Effects of Botulinum Toxin
- 24 Direct Central Nervous System Effects of Botulinum Neurotoxin
- 25 Analgesic Effects of Botulinum Toxins
- 26 Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
- 27 Pharmacology of Botulinum Toxins
- 28 Immunology of Botulinum Toxin Therapy
- 29 Use of Non-A/Non-B Botulinum Toxins
- 30 Clinical Muscular Anatomy for the Botulinum Toxin Injector
- 31 Ultrasound Guidance for Botulinum Toxin Application
- 32 Treatment Algorithms and Injection Schemes for Botulinum Toxin Therapy of Dystonia
- 33 Botulinum Toxin Therapy for Cervical Dystonia
- 34 Botulinum Toxin Therapy for Cranial Dystonia
- 35 Botulinum Toxin Therapy for Spasmodic Dysphonia
- 36 Botulinum Toxin Therapy for Writer’s Cramp and Other Focal Hand Dystonias
- 37 Botulinum Toxin Therapy for Bruxism
- 38 Treatment of Blepharospasm With Eyelid-Opening Apraxia
- 39 Organisation of a Botulinum Toxin Clinic
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
27 - Pharmacology of Botulinum Toxins
from Section II - Botulinum Toxin Therapy
Published online by Cambridge University Press: 31 May 2018
Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- 21 The Global Market for Botulinum Toxin
- 22 Molecular Mechanisms of Botulinum Toxin
- 23 Indirect Central Nervous System Effects of Botulinum Toxin
- 24 Direct Central Nervous System Effects of Botulinum Neurotoxin
- 25 Analgesic Effects of Botulinum Toxins
- 26 Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
- 27 Pharmacology of Botulinum Toxins
- 28 Immunology of Botulinum Toxin Therapy
- 29 Use of Non-A/Non-B Botulinum Toxins
- 30 Clinical Muscular Anatomy for the Botulinum Toxin Injector
- 31 Ultrasound Guidance for Botulinum Toxin Application
- 32 Treatment Algorithms and Injection Schemes for Botulinum Toxin Therapy of Dystonia
- 33 Botulinum Toxin Therapy for Cervical Dystonia
- 34 Botulinum Toxin Therapy for Cranial Dystonia
- 35 Botulinum Toxin Therapy for Spasmodic Dysphonia
- 36 Botulinum Toxin Therapy for Writer’s Cramp and Other Focal Hand Dystonias
- 37 Botulinum Toxin Therapy for Bruxism
- 38 Treatment of Blepharospasm With Eyelid-Opening Apraxia
- 39 Organisation of a Botulinum Toxin Clinic
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Treatment of Dystonia , pp. 128 - 132Publisher: Cambridge University PressPrint publication year: 2018
References
Antonucci, F, Rossi, C, Gianfranceschi, L, Rossetto, O, Caleo, M (2008) Long-distance retrograde effects of botulinum neurotoxin. A J Neurosci 28:3689–3696.CrossRefGoogle ScholarPubMed
Aurora, SK, Dodick, DW, Diener, HC, DeGryse, RE, Turkel, CC, Lipton, RB, Silberstein, SD (2014) OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand 129:61–70.CrossRefGoogle ScholarPubMed
Beard, M (2014) Translocation, entry into the cell. In: Foster, KA (ed.) Molecular Aspects of Botulinum Neurotoxin. New York: Springer; pp151–170.CrossRefGoogle Scholar
Brin, MF, Dressler, D, Aoki, R (2004) Pharmacology of botulinum toxin therapy. In: Jankovic, J, Comella, C, Brin, MF (eds) Dystonia: Etiology, Clinical Features, and Treatment. Philadelphia, PA: Lippincott Williams & Wilkins; pp93–112.Google Scholar
Brin, MF, James, C, Maltman, J (2014) Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics 8:227–241.Google Scholar
de Paiva, A, Meunier, FA, Molgo, J, Aoki, KR, Dolly, JO (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 96:3200–3205.CrossRefGoogle ScholarPubMed
Dressler, D, Benecke, R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34–38.CrossRefGoogle ScholarPubMed
Dressler, D, Rothwell, JC (2000) Electromyographic quantification of the paralysing effect of botulinum toxin. Eur Neurol 43:13–16.CrossRefGoogle ScholarPubMed
Dressler, D, Eckert, J, Kukowski, B, Meyer, BU (1993) Somatosensorisch Evozierte Potentiale bei Schreibkrampf: Normalisierung pathologischer Befunde unter Botulinum Toxin Therapie. Z EEG EMG 24:191.Google Scholar
Dressler, D, Rothwell, JC, Bigalke, H (2000) The sternocleidomastoid test: an in-vivo assay to investigate botulinum toxin antibody formation in man. J Neurol 247:630–632.CrossRefGoogle Scholar
Dressler, D, Adib Saberi, F, Benecke, R (2002) Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 249:1729–1732.CrossRefGoogle ScholarPubMed
Dressler, D, Saberi, FA, Kollewe, K, Schrader, C (2015) Safety aspects of incobotulinumtoxinA high-dose therapy. J Neural Transm 122:327–333.CrossRefGoogle ScholarPubMed
Eleopra, R, Tugnoli, V, Rossetto, O, De Grandis, D, Montecucco, C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Letts 256:135–138.CrossRefGoogle Scholar
Fernández-Salas, E, Wang, J, Molina, Y, Nelson, JB, Jacky, BP, Aoki, KR (2012) Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay. PLoS One 7:e49516.Google Scholar
Filippi, GM, Errico, P, Santarelli, R, Bagolini, B, Manni, E (1993) Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 113:400–404.Google Scholar
Foster, KA (2004) The analgesic potential of clostridial neurotoxin derivatives. Expert Opin Investig Drugs 13:1437–1443.CrossRefGoogle ScholarPubMed
Girlanda, P, Vita, G, Nicolosi, C, Milone, S, Messina, C (1992) Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 55:844–845.Google Scholar
Hallett, M (2015) Explanation of timing of botulinum neurotoxin effects, onset, duration, and clinical ways of influencing them. Toxicon 107:64–67.CrossRefGoogle Scholar
Jabbari, B, Machado, DG (2014) Clinical use of botulinum neurotoxins: pain. In: Foster, KA (ed.) Clinical Applications of Botulinum Neurotoxin. New York: Springer; pp153–176.CrossRefGoogle Scholar
Johnson, EA, Pellett, S, Whitemarsh, RCM, Tepp, WH (2013) Compositions and methods for toxigenicity testing. International Patent Application PCT/US2012/057825.Google Scholar
Kaji, R, Kohara, N, Katayama, M, Kubori, T, Mezaki, T, Shibasaki, H, Kimura, J (1995a) Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer’s cramp. Muscle Nerve 18:234–235.CrossRefGoogle ScholarPubMed
Kaji, R, Rothwell, JC, Katayama, M, Ikeda, T, Kubori, T, Kohara, N, Mezaki, T, Shibasaki, H, Kimura, J (1995b) Tonic vibration reflex and muscle afferent block in writer’s cramp. Ann Neurol 38:155–162.CrossRefGoogle ScholarPubMed
Keller, JE (2006) Recovery from botulinum neurotoxin poisoning in vivo. Neurosci 139:629–637.Google Scholar
Kollewe, K, Escher, C, Fathi, D, Wulff, DU, Paracka, L, Mohammadi, B, Karst, M, Dressler, D (2016) Long-term treatment of chronic migraine with onabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. J Neural Transm 123:533–540.CrossRefGoogle ScholarPubMed
Lange, DJ, Brin, MF, Warner, CL, Fahn, S, Lovelace, RE (1987) Distant effects of local injection of botulinum toxin. Muscle Nerve 10:552–555.Google Scholar
Mazzocchio, R, Caleo, M (2015) More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system. Neuroscientist 21:44–61.CrossRefGoogle Scholar
Pellizzari, R, Rossetto, O, Schiavo, G, Montecucco, C (1999) Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci 354:259–268.CrossRefGoogle ScholarPubMed
Peng, L, Tepp, WH, Pitkin, RM, Johnson, EA, Stenmark, P, Dong, M (2012) Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins. J Cell Sci 125:3233–3242.Google Scholar
Rosales, RL, Arimura, K, Takenaga, S, Osame, M (1996) Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19:488–496.3.0.CO;2-8>CrossRefGoogle ScholarPubMed
Rummel, A (2013) Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Curr Top Microbiol Immunol 364:61–90.Google ScholarPubMed
Schiavo, G, Matteoli, M, Montecucco, C (2000) Neurotoxins affecting neuroexocytosis. Physiol Rev 80:717–766.Google Scholar
Strotmeier, J, Willjes, G, Binz, T, Rummel, A (2012) Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett 586:310–313.CrossRefGoogle ScholarPubMed
Tsai, YC, Moller, BE, Adler, M, Oyler, GA (2014) Molecular basis for persistence of botulinum neurotoxin: the role of intracellular protein degradation pathways. In: Foster, KA (ed.) Molecular Aspects of Botulinum Neurotoxin. New York: Springer; pp191–206.Google Scholar
Wohlfahrt, K, Sycha, T, Ranoux, D, Naver, H, Caird, D (2009) Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin 25:1573–1584.CrossRefGoogle Scholar
- 1
- Cited by